	A			
	Application No.	Applicant(s)		
Notice of Allemaniity	10/009,852	PAPADOPOULOS E	T AL.	
Notice of Allowability	Examiner	Art Unit		
<u> </u>	Jon M. Lockard	1647		
The MAILING DATE of this communication appearance All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication IGHTS. This application is subject to	olication. If not include will be mailed in due of	d course. THIS	
1. This communication is responsive to the Amendment filed	20 September 2005.			
2. \boxtimes The allowed claim(s) is/are <u>92, 95-99, 104-108, 132, 135-1</u>	36, and 138 (renumbered as claims	<u>1-15)</u> .		
3. ☐ Acknowledgment is made of a claim for foreign priority un a) ☐ All b) ☐ Some* c) ☐ None of the:	nder 35 U.S.C. § 119(a)-(d) or (f).			
 Certified copies of the priority documents have 	e been received.			
Certified copies of the priority documents have	been received in Application No	·		
Copies of the certified copies of the priority do	cuments have been received in this i	national stage applicat	ion from the	
International Bureau (PCT Rule 17.2(a)).				
* Certified copies not received:				
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the req	uirements	
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give			OTICE OF	
5. CORRECTED DRAWINGS (as "replacement sheets") mus	st be submitted.			
(a) ☐ including changes required by the Notice of Draftspers		948) attached		
1) ☐ hereto or 2) ☐ to Paper No./Mail Date	•	,		
(b) ☐ including changes required by the attached Examiner's		office action of		
Paper No./Mail Date				
Identifying indicia such as the application number (see 37 CFR 1, each sheet. Replacement sheet(s) should be labeled as such in t			back) of	
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MATERIAL n FOR THE DEPOSIT OF BIOLOGIC	nust be submitted. N AL MATERIAL.	ote the	
	·			
Attachment(s)			•	
1. Notice of References Cited (PTO-892)	Notice of Informal P	atent Application (PTC)-152)	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Dat	(PTO-413), e .		
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date	Paper No./Mail Dat 8), 7. ⊠ Examiner's Amendn	nent/Comment		
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Stateme	ent of Reasons for Allov	wance	
-	9.			

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Valeta Gregg, Ph.D. on 18 November 2005.

The application has been amended as follows:

- 2. Claims 100, 133, 134, and 137 have been cancelled.
- 3. In claim 99, lines 3 and 5, the phrase "SEQ ID NO 15" has been deleted and the phrase -- SEQ ID NO:15-- inserted therefor.
- 4. In claim 105, line 5, the phrase "a suitable host cell" has been deleted and the phrase --a suitable isolated host cell-- inserted therefor.
- 5. Claim 132 (amended) An isolated nucleic acid molecule, consisting of: a nucleotide sequence encoding immunoglobulin-like (Ig) domain 2 of a first vascular endothelial growth factor (VEGF) receptor upstream of a nucleotide sequence encoding Ig domain 3 of a second VEGF receptor and a nucleotide sequence encoding a multimerizing component, wherein the first and second VEGF receptors are each from a different human VEGF receptor protein and wherein the encoded protein is capable of binding VEGF encoding a fusion protein capable of binding vascular endothelial growth factor (VEGF), consisting of

• •	nit: 1647	Page 3
	(a) a VEGF receptor component having immunoglobulin-like (Ig) domains consi	sting of
an Ig	domain 2 of a first VEGF receptor human Flt1 and Ig domain 3 of a second VEGF r	eceptor
<u>huma</u>	an Flt-4; and	
	(b) a multimerizing component.	
6.	In claim 138, line 1, the term "137" has been deleted and the term136	inserted

therefor.

Art Unit: 1647

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Jon M. Lockard**, **Ph.D.** whose telephone number is (571) 272-2717. The examiner can normally be reached on Monday through Friday, 8:00 AM to 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Brenda Brumback**, can be reached on (571) 272-0961.

The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JML November 18, 2005

LORRAINE SPECTOR PRIMARY EXAMINER

Page 4